Compare ORGO & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORGO | WIA |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.6M | 178.2M |
| IPO Year | 2016 | N/A |
| Metric | ORGO | WIA |
|---|---|---|
| Price | $0.97 | $7.69 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 765.7K | 56.4K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.29% |
| EPS Growth | ★ 1600.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $0.93 | $7.45 |
| 52 Week High | $7.08 | $8.54 |
| Indicator | ORGO | WIA |
|---|---|---|
| Relative Strength Index (RSI) | 23.46 | 44.53 |
| Support Level | N/A | $7.53 |
| Resistance Level | $2.57 | $8.24 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 10.03 | 58.88 |
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.